Periodic Reporting for period 4 - BCM-UPS (Dissecting the role of the ubiquitin proteasome system in the pathogenesis and therapy of B-cell malignancies)

The previous clinical success of proteasome inhibitors (e.g. Bortezomib, Carfilzomib) in the treatment of MM and MCL has highlighted the importance of the ubiquitin-proteasome system in these diseases and cancer in general. Moreover, immunomodulatory drugs (IMiDs) like...